Trials & Filings

Celator To Continue AML Trial

DSMB assessment clears trial without modifications

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The independent Data and Safety Monitoring Board (DSMB) for Celator Pharmaceuticals‘ Phase III trial comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has ruled that the trial should continue as planned without any modifications. The DSMB assessment was based on a pre-planned safety...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters